In June of 2017 AveXis announced that based on encouraging data generated by RSRT’s Gene Therapy Consortium it would advance the lead MECP2 gene therapy candidate toward clinical trials.
On 28th February 2018 the company provided an update on its Rett Syndrome program during a conference call to report their 2017 financial results, recent corporate accomplishments and upcoming milestones.
We are delighted and excited with the progress that AveXis has made in advancing the AVXS-201 program. Pending FDA approval it’s likely that a gene therapy clinical trial will start within a year. We will of course keep you informed of future updates.
A huge thank you to all the families, their friends and connections in the UK and beyond who have played a part in this fantastic news.